FIELD: medicine.
SUBSTANCE: invention relates to a copper agonist that binds with copper site binding of amyloid protein-precursor (APP) and/or exerts inhibitory effect on release of amyloid Aβ-peptide. Indicated agonists can be used for treatment of Alzheimer's disease. Also, invention describes methods for detection of copper agonists that bind with copper binding site by contacting APP with different concentrations of these agonists and reveals reducing level of Aβ-peptide in cells of mammals that express amyloid-Aβ-peptide. The advantage of invention involves the development of new agents that can be used for treatment of Alzheimer's disease.
EFFECT: valuable medicinal properties of copper agonist.
8 cl, 1 tbl, 8 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| Aβ-PEPTIDE ANTIBODIES AND APPLICATION THEREOF | 2003 |
|
RU2341533C2 |
| HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
| PEPTIDE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | 2018 |
|
RU2679080C1 |
| HUMANISED ANTIBODIES TO β-AMYLOID PEPTIDE | 2008 |
|
RU2475500C2 |
| METHOD FOR IN VITRO DIAGNOSIS OF ALZHEIMER'S DISEASE USING MONOCLONAL ANTIBODY | 2006 |
|
RU2416619C2 |
| MODULATING AGENT FOR AGGREGATION OF β-AMYLOID FOR AGGREGATION INHIBITION OF NATURAL β-AMYLOID OR FOR TREATMENT OF SUBJECT WITH DISORDER ASSOCIATED WITH β-AMYLOIDOSIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR DETECTION OF NATURAL β-AMYLOID PEPTIDE IN BIOLOGICAL SAMPLE | 2000 |
|
RU2260599C2 |
| ANTIBODY TO AMYLOID BETA | 2013 |
|
RU2651486C2 |
| APPLICATION OF ANTIBODY AGAINST AMYLOID-BETA IN CASE OF EYE DISEASES | 2008 |
|
RU2571859C2 |
